Citius Oncology, Inc. (CTOR)
NASDAQ: CTOR · Real-Time Price · USD
2.060
0.00 (0.00%)
Aug 4, 2025, 4:00 PM - Market closed

Everbridge Stock Forecast

Stock Price Forecast

The 1 analyst with a 12-month price forecast for Everbridge stock has a target of 6.00, which predicts a 191.26% increase from the current stock price of 2.06.

Price Target: $6.00 (+191.26%)
Analyst Consensus: Buy
TargetLowAverageMedianHigh
Price$6.00$6.00$6.00$6.00
Change+191.26%+191.26%+191.26%+191.26%
* Price targets were last updated on Aug 13, 2024.

Analyst Ratings

The average analyst rating for Everbridge stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

RatingMay '25Jun '25Jul '25Aug '25
Strong Buy1111
Buy0000
Hold1111
Sell0000
Strong Sell0000
Total2222

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Maxim Group
Maxim Group
Hold
Downgrades
n/a
HoldDowngradesn/an/aMay 23, 2025
Maxim Group
Maxim Group
Strong Buy
Initiates
$3
Strong BuyInitiates$3+45.63%Nov 27, 2024
EF Hutton
EF Hutton
Strong Buy
Maintains
$6
Strong BuyMaintains$6+191.26%Aug 13, 2024
More Analyst Ratings

Financial Forecast

Revenue This Year
n/a
Revenue Next Year
74.34M
EPS This Year
-0.49
from -0.31
EPS Next Year
0.05
from -0.49
Fiscal YearFY 2022FY 2023FY 2024FY 2025FY 2026FY 2027
Period EndingSep 30, 2022Sep 30, 2023Sep 30, 2024Sep 30, 2025Sep 30, 2026Sep 30, 2027
Revenue
----74.34M106.16M
Revenue Growth
-----42.80%
EPS
-0.32-0.19-0.31-0.490.050.54
EPS Growth
-----960.00%
Forward PE
----40.393.81
No. Analysts
---333
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue202520262027
Highn/a76.5M109.3M
Avgn/a74.3M106.2M
Lown/a71.4M102.0M

Revenue Growth

Revenue Growth202520262027
High--
47.0%
Avg--
42.8%
Low--
37.2%

EPS Forecast

EPS202520262027
High-0.500.050.56
Avg-0.490.050.54
Low-0.470.050.52

EPS Growth

EPS Growth202520262027
High--
991.2%
Avg--
960.0%
Low--
918.4%
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.